Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158.
Xu J, Mao Y, Xu N, Bai Y, Wang D, Chen X, Yin X, Deng Y, Yang J, Zhang J, Tang J, Huang Y, Li J, Luo S, Zheng H, Zhao W, Xu M, Li N, Mao Y, Gozman A, Wu X.
Xu J, et al.
Immunotherapy. 2024 Mar 20. doi: 10.2217/imt-2023-0294. Online ahead of print.
Immunotherapy. 2024.
PMID: 38506258